Nektar Therapeutics (NKTR) Change in Accured Expenses (2010 - 2026)

Nektar Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 91.44% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at -$4.7 million (down 146.14% YoY), while the FY2025 annual figure was -$5.8 million, down 153.9% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $2.3 million, up from -$2.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $14.2 million in Q1 2022, with the low at -$21.5 million in Q4 2022.
• The 5-year median for Change in Accured Expenses is $412000.0 (2023), against an average of -$1.8 million.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses tumbled 770.7% in 2023, then soared 1489.56% in 2024.
• Nektar Therapeutics' Change in Accured Expenses stood at -$21.5 million in 2022, then jumped by 54.77% to -$9.7 million in 2023, then jumped by 32.45% to -$6.6 million in 2024, then jumped by 58.64% to -$2.7 million in 2025, then surged by 185.42% to $2.3 million in 2026.
• Business Quant data shows NKTR's Change in Accured Expenses at $2.3 million in Q1 2026, -$2.7 million in Q4 2025, and -$7.0 million in Q3 2025.